Cartesian Therapeutics (RNAC) Debt to Equity (2016 - 2023)
Cartesian Therapeutics (RNAC) has disclosed Debt to Equity for 9 consecutive years, with -$0.06 as the latest value for Q4 2023.
- On a quarterly basis, Debt to Equity fell 122.98% to -$0.06 in Q4 2023 year-over-year; TTM through Dec 2023 was -$0.06, a 122.98% decrease, with the full-year FY2023 number at -$0.06, down 122.98% from a year prior.
- Debt to Equity was -$0.06 for Q4 2023 at Cartesian Therapeutics, down from $0.37 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $384.79 in Q2 2019 to a low of -$5.97 in Q2 2021.
- A 5-year average of $19.53 and a median of $0.28 in 2022 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: skyrocketed 39198.5% in 2019, then plummeted 425.67% in 2021.
- Cartesian Therapeutics' Debt to Equity stood at $2.25 in 2019, then plummeted by 161.16% to -$1.38 in 2020, then skyrocketed by 182.66% to $1.14 in 2021, then crashed by 75.41% to $0.28 in 2022, then tumbled by 122.98% to -$0.06 in 2023.
- Per Business Quant, the three most recent readings for RNAC's Debt to Equity are -$0.06 (Q4 2023), $0.37 (Q2 2023), and $0.35 (Q1 2023).